Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

23 February 2016 : Original article  

Pretransplant Elevated Plasma Fibrinogen Level is a Novel Prognostic Predictor for Hepatocellular Carcinoma Recurrence and Patient Survival Following Liver Transplantation

Guo-Ying WangABCDEFG, Nan JiangBC, Hui-Min YiBCD, Gen-Shu WangBC, Jian-Wen ZhangCE, Hua LiDF, Jian ZhangBF, Qi ZhangCDF, Yang YangAFG, Gui-Hua ChenAG

DOI: 10.12659/AOT.895416

Ann Transplant 2016; 21:125-130

Abstract

BACKGROUND: Elevated plasma fibrinogen is associated with tumour progression and poor outcomes in several cancers. The present study investigated the prognostic value of preoperative fibrinogen in hepatocellular carcinoma (HCC) patients after liver transplantation (LT).

MATERIAL AND METHODS: We analyzed the preoperative plasma fibrinogen levels of 41 patients who underwent LT for HCC. The cut-off value for elevated level of fibrinogen was determined by using a receiver operating characteristic (ROC) curve analysis. Cox regression analysis was performed to analyze the relationship between elevated fibrinogen level and HCC recurrence. The disease-free survival (DFS) and overall survival (OS) rate after transplantation were calculated by Kaplan-Meier method and compared by log-rank test.

RESULTS: The fibrinogen levels were significantly higher in patients with tumor recurrence (3.31±0.98 g/L) compared with those in patients without recurrence (2.39±0.89 g/L) (P<0.01). A cut-off value for elevated fibrinogen level of 2.675 g/L was defined. Cox regression analysis showed that the relative risk for tumor recurrence increased by 6.871 times for patients with elevated fibrinogen. Eleven patients in the elevated fibrinogen group (21 cases) developed recurrence, while only 2 in the normal fibrinogen group (20 cases) developed recurrence. There were significant differences in DFS and OS between the elevated fibrinogen group and normal fibrinogen group (5-year DFS and OS of 44.0% and 42.9% vs. 89.2% and 80.0%, respectively, P<0.05). Vascular invasion and fibrinogen level ≥2.675 g/L were the independent prognostic predictors of tumor recurrence and poor outcome.

CONCLUSIONS: Pretransplant elevated fibrinogen levels are associated with tumor recurrence and poor prognosis in hepatocellular carcinoma patients after liver transplantation.

Keywords: Fibrinogen, Liver Transplantation, Recurrence

Add Comment 0 Comments

In Press

Case report  

Tongue Carcinoma in Immunosuppressed Patients After Liver and Kidney Transplantation: A Case Series

Ann Transplant In Press; DOI: 10.12659/AOT.951715  

Original article  

Prevalence and Risk Factors of Hepatic Steatosis in Kidney Transplant Recipients

Ann Transplant In Press; DOI: 10.12659/AOT.952251  

Original article  

The Anatomical Landscape of Living Donor Livers: A 101-Case Retrospective Single-Center Study in Indonesia ...

Ann Transplant In Press; DOI: 10.12659/AOT.952031  

Original article  

Decreased Ventilation Duration and ICU Stay Associated With Early Percutaneous Dilatational Tracheostomy Af...

Ann Transplant In Press; DOI: 10.12659/AOT.953143  

Most Viewed Current Articles

24 Aug 2021 : Review article   20,545

Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future Perspectives

DOI :10.12659/AOT.931664

Ann Transplant 2021; 26:e931664

29 Dec 2021 : Original article   16,641

Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...

DOI :10.12659/AOT.933588

Ann Transplant 2021; 26:e933588

05 Apr 2022 : Original article   15,898

Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver Transplantation

DOI :10.12659/AOT.935604

Ann Transplant 2022; 27:e935604

22 Nov 2022 : Original article   15,796

Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...

DOI :10.12659/AOT.937988

Ann Transplant 2022; 27:e937988

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358